Aldevron, a Danaher Corporation company, and Kytopen Corp. have announced a joint marketing agreement aimed at enhancing workflow solutions for cell therapy manufacturers. The collaboration focuses on combining Aldevron's Nanoplasmid™ vector technology with Kytopen's Flowfect Tx™ GMP cellular engineering platform.
This integrated workflow is designed for CRISPR-mediated engineering of primary T Cells, offering high yields and improved cost-effectiveness in cell therapy manufacturing. The Nanoplasmid vector provides high transgene expression and an enhanced safety profile, while Flowfect® technology ensures gentle gene delivery with scalable capacity.
Data from this collaboration, highlighting increased overall yield of final drug substance and simplified manufacturing compared to viral and electroporation technologies, will be presented at the International Society of Cell & Gene Therapy Annual Meeting in May 2025. This partnership is expected to accelerate the adoption of CRISPR-based therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.